logo-loader
viewRedx Pharma Plc

Preclinical data presented at cancer conference

/**/ link{ color: blue }visited{ color: #954F72 } .l{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.l{}p.aa{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.ab{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.ac{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.w{color:black}p.ad{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.ae{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}p.af{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; text-decoration: underline}p.ag{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm} span.q{color:black;background:white}a.p{font-weight: bold}table.ah{width:451.5pt; margin-left:-.75pt}td.o{width:342.75pt;padding:.75pt .75pt .75pt .75pt}td.n{width:105.75pt;padding:.75pt .75pt .75pt .75pt} /**/
RNS Number : 2718G
Redx Pharma plc
05 November 2018
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Preclinical data evaluating RXC004 presented at the NCRI cancer conference

Results demonstrate potential of RXC004 in genetically-defined tumour types

 

Alderley Park, 5 November 2018. Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, is pleased to announce the presentation of positive data from preclinical studies evaluating RXC004 during a poster session, entitled 'Efficacy of the Porcupine inhibitor RXC004 in genetically-defined tumour types' today at the National Cancer Research Institute (NCRI) 2018 Cancer Conference in Glasgow. RXC004 is a novel, oral, potent small molecule Porcupine inhibitor, which targets the Wnt/β-catenin pathway. It is expected to re-enter the clinic in H1 2019 in a Phase 1/2a study in patients with advanced malignancies.

 

The full abstract of the presentation can be found below.

 

Richard Armer, Chief Scientific Officer commented: "We are delighted to showcase some of the fantastic science happening at Redx. We are encouraged by the preclinical data presented at the NCRI, which demonstrates the exquisite sensitivity of specific genetically defined cancer models to our Porcupine inhibitor, RXC004. The strength of these data highlight some of the broad and multiple options available for the future development of this programme as we look to re-enter the clinic in the first half of 2019."

 

NCRI 2018 Abstract

 

Background

Potent and selective porcupine (PORCN) inhibitor RXC004 is being investigated in a Phase 1 clinical trial (NCT03447470). PORCN is a membrane bound O-acyltransferase responsible for post-translational modification of Wnt ligands, essential for Wnt secretion and activity. Wnt pathway alterations, including RNF43 loss-of-function mutations and RSPO fusions, result in increased levels of surface Fzd receptors, increasing Wnt-ligand dependent signalling. These alterations are implicated in colorectal, gastric, pancreatic and biliary cancer. This work assesses the direct tumour targeting effects of RXC004 in genetically selected cancer lines in vitro and in vivo.

 

Method

RXC004 was evaluated in 2D and/or 3D in vitro proliferation assays across a panel of colorectal and pancreatic cancer cell lines. In parallel, cell cycle analysis was assessed using flow cytometry. Downstream markers of target engagement for the Wnt pathway, Axin2 and c-Myc, were analysed for mRNA expression using qPCR. RXC004 was orally dosed for efficacy, PK and PD studies in RNF43 mutant and RSPO fusion xenograft models.

 

Results

RXC004 potently inhibited proliferation in vitro in several genetically selected cell lines. Mechanistically RXC004 arrested the cell cycle at the G1/S and G2/M cell cycle checkpoints. Axin2 mRNA expression was potently inhibited by RXC004 (sub-nM) across all RNF43 mutant and RSPO fusion cell lines tested. Furthermore, inhibition of c-Myc expression correlated with the anti-proliferative effects of RXC004. In contrast, RXC004 had no anti-proliferative effects on APC mutant colorectal cancer cells, and Axin2 and c-MYC expression was not inhibited. In vivo, RXC004 demonstrated significant efficacy and PD responses in multiple RNF43 mutant and RSPO fusion xenograft models.

 

Conclusion

Cancer cells carrying RNF43 mutations or RSPO fusions are sensitive to RXC004 both in vitro and in vivo. This data suggest RXC004 monotherapy would benefit patients with tumours baring RNF43 mutations or RSPO fusions and support a genetically-defined patient selection strategy for ongoing RXC004 clinical studies.

 

 

The poster, entitled 'Efficacy of the Porcupine inhibitor RXC004 in genetically-defined tumour types' presented at the National Cancer Research Institute (NCRI) 2018 Cancer Conference in Glasgow, UK, can be accessed here from noon GMT on 5 November 2018:

https://www.redxpharma.com/app/uploads/2018/11/RXC004-NCRI-2018.pdfE

 

To learn more about our RXC004 inhibitor programme you can visit: https://www.redxpharma.com/programmes/rxc004-porcupine-cancer/

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

Andrew Saunders, Chief Medical Officer

Richard Armer, Chief Scientific Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

About Redx Pharma Plc 

 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RESFSUEELFASEEF

Quick facts: Redx Pharma Plc

Price: 7

Market: AIM
Market Cap: £8.85 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Redx Pharma gets green light to increase dose in lead cancer...

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

on 20/8/19